title: Recognition of DNA modified by antitumor cisplatin by "latent" and "active" protein p53.
abstract: Tumor suppressor protein p53 possesses two DNA-binding sites. One that is located within its core domain is responsible for sequence-specific DNA binding of the protein, non-specific binding to internal segments of single- or double-stranded DNA, and to certain kinds of non-B DNA structures. The other that is contained in the C-terminus of the protein binds to damaged DNA. Binding of active, latent, and in vitro-activated p53 protein to DNA fragments modified by antitumor cisplatin was studied using electrophoretic mobility shift assay in agarose gels and immunoblotting analysis. We found that both latent and active p53 forms bound to random sequences of DNA globally modified by cisplatin with a higher affinity than to unmodified DNA. Interestingly, the latent form exhibited a more pronounced selectivity for platinated DNA than the active p53. Consistently with this observation, the preference of the latent form for platinated DNA decreased as a consequence of the activation of latent p53 by phosphorylation at the protein kinase C site within its C-terminus or by binding of the monoclonal antibody Bp53-10.1. Competition experiments involving a 20-bp consensus sequence of p53 suggested that the p53 core domain was a primary binding site of the active p53 when it bound to DNA fragments lacking consensus sequence, but modified by cisplatin. In addition, the latent protein was found to selectively interact with DNA modified by cisplatin probably via its C-terminus.
authors.affiliation: Laboratory of Biophysical Chemistry and Molecular Oncology, Institute of Biophysics, Academy of Sciences of the Czech Republic, Kralovopolska 135, 612 65, Brno, Czech Republic. fojta@ibp.cz
authors.forename: Miroslav
authors.initials: M
authors.lastname: Fojta
authors.forename: Hana
authors.initials: H
authors.lastname: Pivonkova
authors.forename: Marie
authors.initials: M
authors.lastname: Brazdova
authors.forename: Lucie
authors.initials: L
authors.lastname: Kovarova
authors.forename: Emil
authors.initials: E
authors.lastname: Palecek
authors.forename: Sarka
authors.initials: S
authors.lastname: Pospisilova
authors.forename: Borivoj
authors.initials: B
authors.lastname: Vojtesek
authors.forename: Jana
authors.initials: J
authors.lastname: Kasparkova
authors.forename: Viktor
authors.initials: V
authors.lastname: Brabec
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D001483:Base Sequence; D001665:Binding Sites; D002460:Cell Line; D002945:Cisplatin / Q000633:toxicity*; D004247:DNA / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D009838:Oligodeoxyribonucleotides; D010766:Phosphorylation; D011994:Recombinant Proteins / Q000187:drug effects / Q000378:metabolism; D018411:Spodoptera; D014162:Transfection; D016159:Tumor Suppressor Protein p53 / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D009838:Oligodeoxyribonucleotides; D011994:Recombinant Proteins; D016159:Tumor Suppressor Protein p53; D004247:DNA; D002945:Cisplatin